With the northern Hemisphere officially creeping into summer, the first arguments of this season’s sun and skin debate have arisen
Anti cancer councils and organisations akin to Australia’s Sunsmart are continuing their awareness-raising campaigns, educating the public about the issue, and most importantly the practice of sun protective behaviour; although significant investment and persistence are required, well executed and long running campaigns can make significant progress, albeit on a regional scale. But a vocal group of skeptics are continuing to question whether a central element, sunscreen, might just be part of the problem.
In Australia, Sunsmart and the state Cancer Councils work to educate and inform the public of the consequences of UV exposure and the protective and defensive measures that should be taken in order to avoid sunburn and to decrease the risk of skin cancer and melanoma developing later in life. An important part of changing behaviour in relation to UV exposure is to increase our understanding of the science of UV, sunburn and skin.
As many of you may know, this week saw Clinuvel hold its Annual General Meeting in the Melbourne Town Hall. As managing director I welcome these opportunities where I am able to meet and talk to the people whom Clinuvel considers integral to the company and its existence; the Board of Directors sees Clinuvel’s investors as unique. In Clinuvel, an investor has to fundamentally believe in the premise of offering pharmaceutical photoprotection, a novel option, an innovative approach to skin disorders.
Allergan’s lawsuit filed against the FDA presents a relatively novel case in addressing the requirements of drug developers in relation to off-label use of drugs by physicians.
Following on from 
Manufacturing drugs for human use is a complicated process frequently involving compounds and materials that, if used incorrectly, can be hazardous to people’s health. Highly regulated nations (such as the US, EU, Australia and Canada) have long realised the necessity that they develop strict guidelines governing these processes to protect patients and ensure product safety, quality and efficacy. Poor quality drugs, manufacturing processes or conditions can have extreme and dire consequences for patients. In countries that enforce Good Manufacturing Practice (GMP) the penalties for non-adherence reflect its importance and can include forcing worldwide product recalls, seizure of property, large fines, even imprisonment.
The millisecond transfer of data packs has changed medicine for good. When it comes to gaining online information about our health the pros outweigh the cons. We are seeing in modern medicine that patients are well prepared when seeking health consultation. Sites such as 
This is a continuation of the post 
